News | August 06, 2024
SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Report highlights significant improvements in adolescent well-being in India
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Reported profit after tax declined 19% year-on-year to Rs 76 crores
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
Subscribe To Our Newsletter & Stay Updated
